Sylentis Is A Clinical Stage Biopharmaceutical Company Founded In 2006Specializing In Rna Interferencernaitechnology To Develop Therapies For Ocular Diseasesthe Company Aims To Improve And Extend Vision Through Gene Silencingutilizing Its Proprietary Sirfindera C Platform To Design Specific Sirna Molecules That Target Disease Causing Genes Sylentis Offers Rnai Based Drug Developmentfocusing On Custom Sirna Design For Both Ocular And Non Ocular Targetsthe Company Also Provides Oligonucleotide Development Services And Has Developed Improved Preclinical Models For Retinal Diseaseskey Products Include Tivanisirana Phase Iii Sirna Based Solution For Dry Eye Diseaseand Syl1801Which Targets Age Related Macular Degeneration And Other Retinal Conditionssylentis Is Recognized For Its Innovative Use Of Ai Driven Algorithms To Enhance Therapeutic Precision And Minimize Off Target Effects In Its Drug Development Process
